Vertical data-driven mergers between health insurers and drug suppliers may facilitate health insurers’ efforts to discriminate against vulnerable populations, leaving them without meaningful access to care. Hence, they can widen the existing health inequalities in the United States and perpetuate inequities. However, US antitrust enforcers could address the significant harms that those mergers impose on high-risk consumers. A new wave of data-driven health care mergers is upon us. Health...